Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial-Reference-Cited by-同舟云学术

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Published:2018-01-04 Issue:2 Volume:67 Page:514-523
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Wyles David¹,Poordad Fred²,Wang Stanley³,Alric Laurent⁴^ORCID,Felizarta Franco⁵,Kwo Paul Y.⁶,Maliakkal Benedict⁷,Agarwal Kosh⁸,Hassanein Tarek⁹,Weilert Frank¹⁰,Lee Samuel S.¹¹,Kort Jens³,Lovell Sandra S.³,Liu Ran³,Lin Chih‐Wei³,Pilot‐Matias Tami³,Krishnan Preethi³,Mensa Federico J.³

Affiliation:

1. Denver Health Medical CenterDenver CO

2. The Texas Liver InstituteUniversity of Texas HealthSan Antonio TX

3. AbbVie Inc.North Chicago IL

4. Department of Internal Medicine and Digestive Diseases, CHU Purpan, UMR 152IRD Toulouse 3 UniversityToulouse France

5. Private PracticeBakersfield CA

6. Division of Gastroenterology and HepatologyStanford UniversityPalo Alto CA

7. University of Tennessee Health Science CenterMemphis TN

8. Institute of Liver Studies, Kings College HospitalLondon UK

9. Southern California GI and Liver Centers and Southern California Research CenterCoronado CA

10. Tawa Street Specialist ClinicHamilton New Zealand

11. University of CalgaryCalgary AB Canada